This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2005.06.075v1 46/9/1615    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ginsburg, G. S. Articles by Newby, L. K. Search for Related Content PubMed PubMed Citation Articles by Ginsburg, G. S. Articles by Newby, L. K.

CARDIOVASCULAR GENOMIC MEDICINE

Prospects for Personalized Cardiovascular Medicine

The Impact of Genomics

Geoffrey S. Ginsburg, MD, PhD, FACC^_*,,,_*, Mark P. Donahue, MD, MHS^_*, and L. Kristin Newby, MD, MHS, FACC^_*,

^_* Division of Cardiovascular Medicine, Department of Medicine
Duke Clinical Research Institute
Center for Genomic Medicine, Institute for Genome Sciences & Policy, Duke University, Durham, North Carolina

Manuscript received April 18, 2005; revised manuscript received June 23, 2005, accepted June 30, 2005.

^_* Reprint requests and correspondence: Dr. Geoffrey S. Ginsburg, Center for Genomic Medicine, Institute for Genome Sciences & Policy, CIEMAS, 101 Science Drive, Box 3382, Durham, North Carolina 27708 (Email: geoffrey.ginsburg{at}duke.edu).

Sequencing of the human genome has ushered in prospects for individualizing cardiovascular health care. There is growing evidence that the practice of cardiovascular medicine might soon have a new toolbox to predict and treat disease more effectively. The Human Genome Project has spawned several important "omic" technologies that allow "whole genome" interrogation of sequence variation (re-sequencing, genotyping, comparative genome hybridization), transcription (expression profiling, tissue arrays), proteins (gas or liquid chromatography and tandem mass spectroscopy [MS]), and metabolites (MS or nuclear magnetic resonance profiling); deoxyribonucleic acid, ribonucleic acid, protein, and metabolic approaches all provide more exacting detail of cardiovascular disease mechanisms and, in some cases, are redefining its taxonomy. Pharmacogenomic approaches are emerging across broad classes of cardiovascular therapeutics to assist practitioners in making more precise decisions about which drugs to give to which patients to optimize the benefit-to-risk ratio. Molecular imaging is developing chemical and biological probes that can sense molecular pathway mechanisms that will allow us to monitor health and disease. Together, these tools will enable a paradigm shift from genetic medicine—on the basis of the study of individual inherited characteristics, most often single genes—to genomic medicine, which by its nature is comprehensive and focuses on the functions and interactions of multiple genes and gene products, among themselves and with their environment. The information gained from such analyses, in combination with clinical data, is now allowing us to assess individual risks and guide clinical management and decision-making, all of which form the basis for cardiovascular genomic medicine.

Abbreviations and Acronyms   ACE = angiotensin-converting enzyme   ACS = acute coronary syndromes   BNP = brain natriuretic peptide   CAD = coronary artery disease   CI = confidence interval   CK = creatine kinase   CVD = cardiovascular disease   FLAP = 5-lipoxygenase accessory protein   hs-CRP = high-sensitivity C-reactive protein   LQT = long QT   MEF2A = member of the myocyte enhancer factor 2 transcription factor family   MI = myocardial infarction   MS = mass spectroscopy   NMR = nuclear magnetic resonance   PUFA = polyunsaturated fatty acid   RR = relative risk   SNP = single nucleotide polymorphism

This article has been cited by other articles:

				G. S. Ginsburg, S. H. Shah, and J. J. McCarthy Taking Cardiovascular Genetic Association Studies to the Next Level J. Am. Coll. Cardiol., September 4, 2007; 50(10): 930 - 932. [Abstract] [Full Text] [PDF]

				F. A. Jaffer, P. Libby, and R. Weissleder Molecular Imaging of Cardiovascular Disease Circulation, August 28, 2007; 116(9): 1052 - 1061. [Full Text] [PDF]

				J. Tegner, J. Skogsberg, and J. Bjorkegren Thematic review series: Systems Biology Approaches to Metabolic and Cardiovascular Disorders. Multi-organ whole-genome measurements and reverse engineering to uncover gene networks underlying complex traits J. Lipid Res., February 1, 2007; 48(2): 267 - 277. [Abstract] [Full Text] [PDF]

				A. N. DeMaria, O. Ben-Yehuda, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, J. Narula, D. J. Sahn, et al. Highlights of the Year in JACC 2006 J. Am. Coll. Cardiol., January 30, 2007; 49(4): 509 - 527. [Full Text] [PDF]

				S. Anwaruddin, A. T. Askari, and E. J. Topol Redefining Risk in Acute Coronary Syndromes Using Molecular Medicine J. Am. Coll. Cardiol., January 23, 2007; 49(3): 279 - 289. [Abstract] [Full Text] [PDF]

				M. Srinivasan, C. R. Keenan, and J. Yager Visualizing the Future: Technology Competency Development in Clinical Medicine, and Implications for Medical Education Acad Psychiatry, December 1, 2006; 30(6): 480 - 490. [Abstract] [Full Text] [PDF]

				G. J. Hankey Potential New Risk Factors for Ischemic Stroke: What Is Their Potential? Stroke, August 1, 2006; 37(8): 2181 - 2188. [Abstract] [Full Text] [PDF]

				P. Kohli and P. Greenland Role of the Metabolic Syndrome in Risk Assessment for Coronary Heart Disease JAMA, February 15, 2006; 295(7): 819 - 821. [Full Text] [PDF]